483
ICON plcFDA 483 - ICON plc - October 24, 2025
Discuss this record with AI
Record Details
An FDA inspection of ICON plc's bioanalytical facility in Assen, Netherlands, identified a significant issue with method validation. The firm failed to adequately evaluate the specificity of bioanalytical methods for certain compounds in the presence of all co-administered medications. This indicates a potential deficiency in the rigor of their method validation processes.
Open in Dashboard
ID · c0f89508-84d8-45c1-9457-76c0e87b951e